MRK1N Stock Chart & Stats
$2814.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$2,814.00 - $3,299.85
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$1.38T
Enterprise Value$74.31B
Total Cash (Recent Filing)$1.96B
Total Debt (Recent Filing)$12.30B
Price to Earnings (P/E)27.8
Beta-0.02
Next Earnings
Nov 12, 2026EPS Estimate
45.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.45
Shares Outstanding129,242,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)1.86
Price to Sales (P/S)2.53
P/FCF Ratio22.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,152.80Price Target Upside― Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)178.77
Revenue Forecast (FY)$453.19B
Bulls Say, Bears Say
Bulls Say
Manageable LeverageManageable leverage and a larger equity base support financial resilience across Merck KGaA’s three businesses. Lower balance-sheet pressure preserves flexibility to fund research, product development, and operating needs while reducing the strain that heavier debt could place on future cash flows.
Healthy MarginsHealthy gross and operating margins indicate that Merck KGaA retains meaningful profitability across its healthcare, life science, and electronics activities. This margin profile can help absorb uneven demand, support continued investment in innovation, and provide a durable foundation for earnings when growth improves.
Positive Free Cash FlowMeaningfully positive and improving trailing free cash flow demonstrates that the company is converting its operations into funds available for investment and capital allocation. Sustained cash generation strengthens financial self-funding capacity and supports resilience through periods of uneven earnings or revenue growth.
Bears Say
Uneven Revenue GrowthFlat revenue across three annual periods points to inconsistent expansion rather than a steadily compounding top line. Although the TTM rebound is encouraging, the uneven pattern makes future growth less predictable and increases the importance of sustained demand and execution across the company’s sectors.
Declining Recent EarningsRecent net income below prior annual levels shows that strong gross and operating margins have not translated into a comparable earnings peak. Persistent pressure on bottom-line performance could limit internal funding, reduce returns from the existing asset base, and weaken the durability of earnings growth.
Moderate Cash ConversionModerate and volatile conversion of net income into free cash flow reduces the reliability of reported profits as a source of deployable capital. Even with a TTM recovery, recurring conversion below earnings can constrain investment flexibility and make cash-based performance more sensitive to operating fluctuations.
MRK1N FAQ
What was Merck KGaA’s price range in the past 12 months?
Merck KGaA lowest stock price was $2814.00 and its highest was $3299.85 in the past 12 months.
What is Merck KGaA’s market cap?
Merck KGaA’s market cap is $1.38T.
When is Merck KGaA’s upcoming earnings report date?
Merck KGaA’s upcoming earnings report date is Nov 12, 2026 which is in 11 days.
How were Merck KGaA’s earnings last quarter?
Merck KGaA released its earnings results on Aug 06, 2026. The company reported $45.471 earnings per share for the quarter, beating the consensus estimate of $42.65 by $2.821.
Is Merck KGaA overvalued?
According to Wall Street analysts Merck KGaA’s price is currently Undervalued.
Does Merck KGaA pay dividends?
Merck KGaA does not currently pay dividends.
What is Merck KGaA’s EPS estimate?
Merck KGaA’s EPS estimate is 45.87.
How many shares outstanding does Merck KGaA have?
Merck KGaA has 129,242,250 shares outstanding.
What happened to Merck KGaA’s price movement after its last earnings report?
Merck KGaA reported an EPS of $45.471 in its last earnings report, beating expectations of $42.65. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Merck KGaA?
Currently, no hedge funds are holding shares in MX:MRK1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3,152.80 (― Upside)
$3,152.80 (― Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.23%
12-Months-Change
Fundamentals
Return on Equity
8.08%
Trailing 12-Months
Asset Growth
11.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.